Best Peptides for Longevity and Bioregulators in 2026

Epithalon (Ala-Glu-Asp-Gly) is the single most-studied Khavinson bioregulator, with more than 35 years of research led by Khavinson himself. Its proposed mechanism — telomerase activation plus normalization of pineal melatonin output — is the most mechanistically specific in the category. Animal lifespan studies report roughly 13% extension in mice, and a 15-year human observational cohort suggested a 1.6–1.8x mortality reduction when combined with thymalin. It remains the anchor of the Khavinson protocol and the benchmark every other longevity peptide is measured against.

Pinealon (Glu-Asp-Arg) is a pineal tripeptide isolated as an active fraction of cortexin. Russian clinical reports describe improvements in memory, attention, and psychomotor response time in elderly subjects, and PMC-indexed mouse work shows reduced amyloid-related pathology and improved hippocampal neuron survival. Mechanistically it upregulates neuroprotective genes including nestin, GAP-43, and SOD. It sits one layer deeper in the CNS-longevity stack than epithalon — same bioregulator family, more targeted at cognitive aging.

Thymalin is a thymic peptide bioregulator derived from bovine thymus extracts and approved as a pharmaceutical in Russia since 1982. It is proposed to partially reverse immunosenescence — normalizing CD4/CD8 ratios, enhancing NK cell activity, and modulating neuroendocrine-immune signaling. The Khavinson long-term cohort followed elderly patients for 6–15 years after combined thymalin + epithalon treatment and reported meaningful mortality reductions versus controls. It is the immune-axis counterpart to epithalon and the second pillar of the classical bioregulator protocol.

Vilon is the minimal-viable Khavinson peptide — a dipeptide (Lys-Glu) studied primarily as an immune bioregulator and broader anti-aging agent. Russian preclinical work reports enhanced T-cell function, increased thymus weight in aged mice, and modest lifespan extension. Its extremely short length is of interest because it pushes the bioregulator hypothesis to its limit: if a dipeptide can still produce tissue-specific epigenetic effects, the model's mechanistic claims become more testable. Clinically it is usually deployed alongside thymalin and epithalon.

Cortexin is a polypeptide complex extracted from bovine cerebral cortex and registered as a prescription drug in Russia since 1999 for stroke, traumatic brain injury, and cognitive impairment. It contains water-soluble peptide fractions (1,000–10,000 Da) that cross the blood-brain barrier and modulate excitatory/inhibitory neurotransmitter balance, oxidative stress, and neuroplasticity. Comparative Russian trials show neuroprotective effects in line with cerebrolysin and actovegin in acute brain ischemia. Its role in a longevity stack is neurotrophic support rather than mechanism-specific life extension.

Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide derived from the same cortical bioregulator family as cortexin. Transcriptomic work on cortagen-treated cells reports changes across roughly 110 genes spanning 234 DNA regions — one of the more specific datasets supporting the epigenetic-regulator hypothesis. In peripheral nerve injury models, cortagen produced up to a 40% increase in regenerating nerve fiber counts. Western RCTs do not exist; the evidence base is Russian-language preclinical and observational work.

Adamax is a newer synthetic neuropeptide built on the N-acetyl semax backbone with an adamantyl modification borrowed from P21. The adamantyl group increases lipophilicity, protects against peptidase degradation, and enhances blood-brain barrier penetration. Proposed mechanism is BDNF upregulation and TrkB sensitization in the hippocampus. Unlike the classical Khavinson bioregulators, adamax has essentially no independent peer-reviewed clinical literature as of 2026 — its inclusion here is mechanistic and exploratory rather than evidence-heavy.

Cerebrolysin is the outlier on this list. It is not a pure peptide but a mixture of low-molecular-weight peptides and free amino acids derived from porcine brain tissue by controlled enzymatic proteolysis. Unlike the rest of the ranking, it has a genuine large-scale Western-adjacent evidence base: the CASTA trial (1,070 patients) in acute ischemic stroke, multiple Alzheimer's meta-analyses showing ADAS-cog improvement, and a Cochrane review that rates the stroke evidence as 'promising but not conclusive.' It is approved as a prescription drug in 40+ countries — but not the US.

Retinalamin is a retinal bioregulator peptide complex developed within the Khavinson program and used in Russian ophthalmology for age-related macular degeneration, diabetic retinopathy, and glaucoma. It is proposed to support photoreceptor survival, modulate retinal pigment epithelium function, and reduce oxidative stress in retinal tissue. It is the organ-specific bioregulator most tightly indexed to a measurable late-life disease — vision loss — which makes it an interesting longevity-adjacent compound even though its evidence base is narrowly ophthalmological.

Chonluten is the lung-specific Khavinson bioregulator, a tripeptide studied for respiratory immune support, bronchial epithelium regeneration, and mucosal defense. It is used in Russian pulmonology protocols for chronic bronchitis, COPD, and post-viral respiratory recovery. It is often stacked with thymalin or LL-37-family peptides when the goal is specifically respiratory rather than systemic immune support. As with other organ-specific bioregulators, Western clinical data are essentially absent.

Ovagen is the hepatic Khavinson bioregulator, a short peptide proposed to modulate liver protein synthesis, detoxification enzyme activity, and hepatocyte regeneration in aging. Russian observational studies describe use in chronic hepatitis recovery and liver steatosis protocols. It rounds out the organ-specific coverage of the Khavinson family (thymus, pineal, cortex, lung, retina, liver) and is typically stacked inside a rotation rather than used as a standalone anti-aging agent.